分子病態治療研究センター

菊池 次郎

キクチ ジロウ  (Jiro Kikuchi)

基本情報

所属
自治医科大学 分子病態治療研究センター 領域融合治療研究部 准教授
学位
医学博士(自治医科大学)

J-GLOBAL ID
201401084114006952
researchmap会員ID
B000237863

外部リンク

論文

 91
  • Jiro Kikuchi, Naoki Osada, Sae Matsuoka, Tomomi Ohta, Hirotaka Kazama, Heigoro Shirai, Marco Meloni, Marielle Chiron, Hiroshi Yasui, Hideki Nakasone, Yusuke Furukawa
    Haematologica 111(1) 385-391 2026年1月1日  
  • Jiro Kikuchi, Naoki Osada, Sae Matsuoka, Hiroshi Yasui, Yusuke Furukawa, Hideki Nakasone
    Leukemia 40(1) 211-214 2026年1月  
  • Naoki Osada, Jiro Kikuchi, Sae Matsuoka, Hiroshi Yasui, Sho Ikeda, Naoto Takahashi, Yusuke Furukawa, Hideki Nakasone
    Cells 14(7) 2025年3月21日  
    Multiple myeloma (MM) is the second most common hematologic malignancy and has a poor prognosis. Although the outcomes of MM have markedly improved with the approval of novel agents, the high incidence of relapse means that MM remains incurable. The bone marrow microenvironment (BMME) contributes to drug resistance and minimal residual disease (MRD), which is a major source of relapse in patients with MM. However, the underlying molecular mechanisms are not fully understood. We have previously shown that the upregulation of the AP-1 transcription factor c-FOS confers lenalidomide resistance by maintaining IRF4 expression in MM cells. In this study, we show that upregulated expression of c-FOS confers a poor prognosis and cancer stem cell-like features, including drug resistance, within BMME, both in vitro and in vivo, via IRF4 upregulation; and that inhibition of c-FOS by the AP-1 inhibitor, T-5224, prevents regeneration of MM cells via IRF4 downregulation in a murine serial transplantation assay. These results suggest a functional role for c-FOS in conferring cancer stem cell-like features to MM cells in the BMME for the first time. Therefore, c-FOS inhibition may be an effective treatment strategy for improving the outcomes of patients with MM by eliminating drug-resistant cancer stem cell-like MM cells in MRD.
  • Sae Matsuoka, Naoki Osada, Hirokazu Kubota, Ko Kikuzato, Hiroo Koyama, Takeshi Sonoda, Akiko Idei, Minoru Yoshida, Masaki Kikuchi, Takashi Umehara, Chiduru Watanabe, Teruki Honma, Hiroshi Yasui, Sho Ikeda, Naoto Takahashi, Hideki Nakasone, Jiro Kikuchi, Yusuke Furukawa
    Blood Neoplasia 100091-100091 2025年3月  
  • Nakanobu Hayashi, Chikako Abel, Jiro Kikuchi, Momoko Hayashi, Sakura Hayashi, Masahiro Ueda, Koyu Suzuki, Masahiko Sugitani, Hiroaki Taniguchi, Toru Wake, Yusuke Furukawa
    Archives of Clinical and Biomedical Research 2024年12月2日  
    <jats:title>Abstract</jats:title> <jats:p>The development of mRNA vaccines and oral drugs against SARS-CoV-2 has been useful in protecting against Covid-19 infection. Since then, however, many variants of delta and omicron strains with enhanced infectivity and immune escape capacity have emerged. A 7-amino acid random peptide ribosome display library screening system was used to perform a rapid in vitro screening of peptide aptamers that universally bind to the SARS-CoV-2 wild-type, delta, and Omicron variant BA.1, BA.2, and BA.5 spike RBD (Receptor Binding Domain). Screening resulted in four peptide aptamers that showed positive binding reactions in ELISA. Interestingly, Amino Acid Sequence Determination of the four clones predicted that three of the four clones contain 2 ~ 3 Cys residues in their sequences, forming a complex higher-order structure with disulfide (S-S) bonds. The 7-amino acid random peptide ribosome display library screening system allows for rapid in vitro screening of peptide aptamers that bind to other unknown emerging infectious disease pathogens that may be pandemic in the future. The peptide aptamers are as small as 30 amino acids and can be easily synthesized and purified as peptides or proteins, or simply used as mRNA drugs.</jats:p>

講演・口頭発表等

 73

共同研究・競争的資金等の研究課題

 36

主要な産業財産権

 9

メディア報道

 6